Dry Eye

Harrow announced that starting in January 2025, Vevye will be covered under key Medicare Part D formularies and across major insurance programs, expanding access to the dry eye disease treatment for millions of patients, particularly older adults.

Joanne F. Shen, MD, director of the dry eye clinic at Mayo Clinic's campus in Phoenix, Arizona, and a research team studied 35 patients treated with IPL/MGX. The team reviewed demographics, ocular histories, Standard Patient Evaluation of Eye Dryness 2 symptom survey scores, slit-lamp examinations and meibomian gland evaluations at baseline and at each visit before IPL/MGX treatments.

The authors reported significant variability in DED-related symptoms, with higher prevalence rates among university students and administrative workers.

John D. Sheppard, MD, MMSc, FACS, spoke with the Eye Care Network to provide some insight on post hoc analysis of the ESSENCE 1 trial dor dry eye disease.

The resubmission comes after receiving a Complete Response Letter at the end of 2023.

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease.

During a presentation at EyeCon 2024, Jennifer Loh, MD, of Loh Ophthalmology Associates in Miami, Florida, discussed advances in anterior segment technology, focusing on dry eye treatments and new surgical technologies for intraocular lenses.

IVW-1001 is a novel TRPM8 agonist delivered via ophthalmic eyelid wipe, being developed to treat DED.

The companies’ eye care line will feature refreshed design and improved packaging for Ocucyn Eyelid and Eyelash Cleanser. The full line will be introduced at the American Academy of Ophthalmology's annual meeting in Chicago.

The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in 4Q calendar year 2024. Topline results currently are expected in late 2025

Physicians share comprehensive approaches during roundtable discussion.

Results suggest higher exposures to lower temperatures and certain air pollutants could result in worsened ocular symptoms and increased tear osmolarity.

Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry at EyeCon.

The companies announced that they will be working to develop SGN’s micellar nanoparticle platform to be used with Eyenovia’s Optejet dispenser.

The positive opinion from the CHMP comes with the recommendation that Vevizye be granted marketing authorization for the treatment of dry eye disease in the European Union.

According to Allgenesis Biotherapeutics, AG-8030 is a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of DED.

Dry eye experts discuss the future of dry eye management.

Dry eye experts discuss Cyclosporine ophthalmic solution.

Dry eye experts discuss how they use a comprehensive dry eye diagnostic approach to tailor and customize individual patients.

Dry eye experts discuss how they tailor dry eye treatment based on diagnostic test results and other factors.

Dry eye experts discuss how they use a comprehensive dry eye diagnostic approach to tailor and customize individual patients.

Dry eye experts discuss how they use a comprehensive dry eye diagnostic approach to tailor and customize individual patients.

Dry eye experts discuss tear film assessment techniques and emphasize the importance of distinguishing between aqueous-deficient and evaporative dry eye for targeted treatment approaches.

The collaboration agreement will allow the 2 companies to find a potential new treatment for chronic dry eye disease.

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.